Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Partech in connection with its investment in Billogram
Mandate

Vinge has advised Partech in connection with its investment in Billogram

September 14, 2021 M&A

Vinge has advised global tech investment firm Partech with its 35 MEUR investment into Billogram.

The new capital will go directly into Billogram's expansion into six new markets and doubling its workforce. Partech is known for investing in global European-born software leaders Ecovadis, M-Files or Sendinblue, unicorns such as Jellysmack, Rohlik, Sorare, Toss and Swedish digital native fashion brand NA-KD. Billogram provides a customer relationship-strengthening software platform that secures payments on time, increases customer satisfaction, and prevents churn.

Vinge’s team primarily consisted of Johan Larsson, Ulrich Ziche, Maria Dahlin Kolvik, Rickard Vernet, Selma Beganovic, Daniel Daun and Johanne Örnfeldt Svensson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026